210 filings
Page 4 of 11
8-K
lbfbkcnjg1p89d93 w1p
13 May 21
Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:44pm
DEFA14A
i2p xlozmcl9q
30 Apr 21
Additional proxy soliciting materials
2:32pm
8-K
t3qjww8e
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
svevexxy5yg 0adom4
19 Apr 21
OVID Provides Update on OV101 Program and the Prioritization of its Resources
8:31am
8-K
nkc3foiog xsb226mq
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
ccfk7zu gahuh17
1 Apr 21
Termination of a Material Definitive Agreement
4:52pm
8-K
s8nwlwf9122f7
30 Mar 21
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
8:05am
CT ORDER
nkntvij
18 Mar 21
Confidential treatment order
12:00am
S-8
9rz vhyjy5zjuz
18 Mar 21
Registration of securities for employees
12:00am
8-K
zxmzz
15 Mar 21
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
8:05am
8-K
x12vn9yp1ndq6mymg22a
3 Mar 21
Regulation FD Disclosure
10:05am
8-K
nx6hg1
3 Mar 21
Entry into a Material Definitive Agreement
7:05am
8-K
otwuc52ii8rakumwl
21 Dec 20
Departure of Directors or Certain Officers
5:26pm
8-K
nsihwgil6rrq
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
EFFECT
l6b mk5s4jv7kb
23 Nov 20
Notice of effectiveness
12:18am
424B5
m9aogfv6x
20 Nov 20
Prospectus supplement for primary offering
4:23pm
CORRESP
0kp6a0cm2 2r59j8edh
18 Nov 20
Correspondence with SEC
12:00am